Thursday's Winners & Losers: Bear Stearns Shares Bear Up Well

Genentech closed up 63 cents, or 0.9%, at $67.97 on Thursday.

Also on the decline on Thursday, Array BioPharma (ARRY Quote), which delivered disappointing news on Wednesday after the closing bell. Array said that AZD6244, an experimental treatment for advanced melanoma, failed to meet its primary goal in a midstage trial. Subsequently, its co-developer AstraZeneca (AZN Quote) has opted not to take the drug to late-stage development. Array slid $3.06, or 28%, to $7.96, and Astra Zeneca traded down 35 cents, or 0.8%, to $43.95.

BlackBerry maker Research In Motion(RIMM Quote) gained 4.8% ahead of its third-quarter earnings after the market close Thursday. Analysts are expecting EPS of 62 cents on revenue of $1.65 billion, compared with earnings of 31 cents a share on revenue of $835 million a year ago. For the fourth quarter, analysts are expecting EPS of 65 cents on revenue of $1.74 billion. The stock was up $4.86 to $106.99.

Accenture(ACN Quote) added $2.28, or 6.5%, to $37.24 after the company reported higher-than-expected earnings for the first quarter and raised guidance. Accenture said revenue increased 19% to $5.67 billion in the quarter and it reported EPS of 60 cents. That was higher than analysts' expectations of revenue of $5.45 billion and earnings of 56 cents a share. For the full fiscal year, Accenture raised its EPS outlook for the full year by 15 cents to a range of $2.36 to $2.41. Analysts were expecting EPS of $2.26 for the full year.